Kenya BioVax Institute Limited

Home
Kenya
Nairobi
Kenya BioVax Institute Limited

Our mandate is to manufacture, package and commercialize specialized health products in Kenya.

18/12/2025

Prof. Paul Lavalni, Founder and Executive Director of Empower School of Health, paid a courtesy call to Kenya BioVax Institute Limited, where he met with CEO Dr. Wesley Ronoh to explore potential areas of strategic partnership. The discussions focused on opportunities for collaboration in health systems strengthening, capacity building, and advancing shared goals in public health and local health innovation, reinforcing a mutual commitment to impactful, sustainable health solutions.

🇰🇪 🇺🇸 🇮🇳 🇨🇭

17/12/2025

The World Bank's assessment confirms that the facility now complies with biosafety and environmental standards and aligns with the World Health Organisation’s Good Manufacturing Practices (GMP)...

15/12/2025

Kenya races to end vaccine shortages with first local production targeted for 2027

Read more: https://zurl.co/FGw2x

11/12/2025

Kenya BioVax Institute joins the nation in celebrating Jamhuri Day, a moment to honour our journey of self-determination, resilience, and national progress. As we work to build a modern vaccine and biologics manufacturing ecosystem for Kenya and the region, we reaffirm our commitment to advancing health security, strengthening local production, and contributing to a healthier, self-reliant nation.

Happy Jamhuri Day to all Kenyans ! 🇰🇪

10/12/2025

Mr. Gerald Macharia, Vice President for East and Southern Africa and Country Director for Kenya at the Clinton Health Initiative (CHAI), paid a courtesy call to Dr. Wesley Ronoh, Chief Executive Officer of Kenya BioVax Institute. Their discussion focused on potential areas of partnership and collaboration, particularly in strengthening local vaccine manufacturing, advancing technology transfer, and building sustainable production capacity. Mr. Macharia further held an engagement with the Kenya BioVax technical team, where they explored deeper avenues for collaboration and alignment on scientific, regulatory, and operational priorities. The visit underscored CHAI’s commitment to supporting regional health security and Kenya BioVax’s role in driving the country’s path toward vaccine self-reliance.

09/12/2025

Kenya BioVax Institute Limited was honoured to participate in the Pharmaceutical Manufacturing Investors’ Breakfast Meeting hosted by the Kenya Development Corporation (KDC), a forum dedicated to accelerating Kenya’s shift from import dependence to strong local pharmaceutical production. Our CEO, Dr. Wesley Ronoh, reaffirmed BioVax’s strategic role in developing a modern end-to-end vaccine and biologics manufacturing ecosystem, emphasizing the need for coordinated investment, technology transfer, and capacity building to enhance national competitiveness.

We welcomed discussions on policy incentives, expansion opportunities, and financing pathways, aligned with KDC Director General Ms. Norah Ratemo ’s call for patient capital to anchor the sector.

BioVax remains committed to working with government, investors, and industry partners to strengthen local manufacturing of Health Products and Technologies and support Kenya’s drive toward a resilient, self-sufficient healthcare system.

Africa CDC

09/12/2025

Strengthening vaccine manufacturing capacity through participation in the Africa CDC Biomanufacturing Fellowship

Kenya BioVax Institute is proud to celebrate the successful completion of the Africa Centres for Disease Control and Prevention (Africa CDC) Biomanufacturing Fellowship by our Production Scientist, Dr. Jones Mutua, who joined a distinguished cohort of African experts for an intensive study tour across leading vaccine manufacturing institutions in Egypt. Through hands-on training in Research and Development (R&D), Manufacturing Sciences and Technology (MSAT), Technical Operations, Quality Control (QC), Quality Assurance (QA), Regulatory Affairs, and Engineering, the fellowship equipped participants with advanced skills essential for strengthening Africa’s vaccine self-reliance agenda. This achievement marks a significant step in enhancing Kenya BioVax’s technical capacity as we continue building Kenya’s end-to-end vaccine manufacturing ecosystem and contributing to the continent’s long-term goal of producing 60% of its vaccines locally by 2040.

🇰🇪 🧬

05/12/2025

Kenya is set to have its first batch of locally manufactured immunisation vaccines on trial by end of 2027, following the completion of the first phase of enabling works for the manufacturing plant.

04/12/2025

The World Bank team has concluded an assessment of the Kenya BioVax Institute Limited's Embakasi facility, highlighting the completion of Phase 1 enabling works in Kenya's flagship vaccine manufacturing programme. This evaluation marks an important step in the project's milestone-based progression and positions BioVax to advance into Phase 2, which will include the installation of high-precision fill–finish machinery and the establishment of advanced quality-control laboratories. The enabling works—covering structural upgrades, water treatment systems, power stabilization, Heating, Ventilation, and Air Conditioning (HVAC) installation, biosafety and environmental compliance, and World Health Organization (WHO) Good Manufacturing Practices (GMP)–aligned sterile manufacturing pathways—demonstrate Kenya's readiness to operationalize a modern vaccine production hub. As Africa advances toward its goal of producing 60% of its vaccines locally by 2040, the progress at Embakasi marks a significant step in strengthening national and continental health security.

03/12/2025

Final Feasibility Report Launched: Paving the Way for Kenya’s End-to-End Vaccine Production

Kenya today hosted the Final Meeting and Launch of the Final Feasibility Report for the Smart Vaccine Manufacturing Facility Project, marking a pivotal step toward establishing a modern end-to-end vaccine manufacturing ecosystem in the country. Building on last year's Interim Report, the Final Study reflects extensive consultations across policy, research, academia, and industry. It outlines a clear roadmap for developing a facility capable of producing safe, effective, and affordable vaccines for Kenya and the region. The event brought together senior government officials, BioVax leadership, the Kenya Vaccine Consortium (AtkinsRéalis, SK bioscience, and IVI), and experts from regulatory, academia, and research institutions.

In his remarks, Dr. Charles Githinji, Chairperson of the Kenya BioVax Institute Board, highlighted the project's strategic significance and reaffirmed the Board's commitment to guiding Kenya BioVax Institute Limited into the implementation phase. Mr. James Ntabo, who represented the Ministry of Health, commended the strong inter-agency collaboration that has shaped the feasibility study and emphasized the Government's support for advancing local vaccine manufacturing. H.E. Amb. Kang Hyung-shik also reiterated Korea's long-standing partnership with Kenya.

Today’s milestone further strengthens ongoing progress under the
World Bank–supported fill-finish project (in Embakasi), ensuring alignment between the feasibility study’s recommendations and the practical enabling works already underway at BioVax. Together, these complementary initiatives position Kenya to build a fully integrated and future-ready vaccine manufacturing platform.
🇰🇪🇰🇷

AAfrica CDC

02/12/2025

H.E. Hatem Yousri Hosni, Ambassador of the Arab Republic of Egypt to Kenya, together with the senior technical team from Minapharm Pharmaceuticals–Egypt, paid a courtesy call on Kenya BioVax Institute CEO, Dr. Wesley Ronoh. The engagement centred on exploring strategic partnerships in technology transfer, local vaccine and biopharmaceutical manufacturing, and advancing Africa’s collective health security agenda. BioVax and Minapharm reaffirmed their commitment to collaborative innovation aimed at strengthening regional production capacity and accelerating access to quality, affordable biologics across the continent.

🇰🇪🇪🇬🌍

🧬 🔬 🧫

21/11/2025

Kenya BioVax Institute (KBI) today hosted a courtesy call led by Anne-Claire Amprou, the French Ambassador for Global Health, accompanied by Dr. Serawit Bruck Landais, Global Health Advisor for East Africa and Somalia. The delegation was received by KBI’s CEO, Dr. Wesley Ronoh, together with senior leadership, including Dr. Cecilia Wanjala (GM, Commercial Services), Dr. Serah Muteru (GM, Regulatory Affairs, Product Quality & Safety), and Prof. Richard Oduor (GM, Research & Technology Transfer). Discussions focused on strategic areas of collaboration, including technology transfer of KBI’s preferred antigen portfolio, strengthening research and development capabilities, and enhancing tech-transfer readiness. The meeting also explored Kenya’s evolving regulatory landscape in preparation for local vaccine manufacturing, as well as opportunities for market access through the African Pooled Procurement Mechanism. Additionally, the teams deliberated on KBI’s potential participation in the upcoming high-level France–Kenya Summit in May 2026, where KBI could showcase its growing role in advancing local vaccine production and regional health security.

🇰🇪 🇫🇷🇰🇪 French Embassy in Kenya and Somalia

Address

40779
Nairobi
00100

Telephone

+254775751639

Website

https://biovax.go.ke/homepage

Alerts

Be the first to know and let us send you an email when Kenya BioVax Institute Limited posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Kenya BioVax Institute Limited:

Shortcuts

Want your practice to be the top-listed Clinic in Nairobi?

Kenya BioVax Institute Limited

18/12/2025

17/12/2025

15/12/2025

11/12/2025

10/12/2025

09/12/2025

09/12/2025

05/12/2025

04/12/2025

03/12/2025

02/12/2025

21/11/2025

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category